Barinthus Biotherapeutics Appoints New Chief Scientific Officer

An announcement from Barinthus Biotherapeutics ( (BRNS) ) is now available.

Barinthus Biotherapeutics has announced the promotion of Geoffrey Lynn, M.D., Ph.D., as the new Chief Scientific Officer, succeeding Nadège Pelletier, Ph.D. This leadership change comes as the company advances its innovative immunotherapeutic pipeline, including promising treatments for chronic hepatitis B and celiac disease. Investors in the biotech sector can look forward to Dr. Lynn’s expertise in driving the development of cutting-edge therapies that aim to tackle autoimmune diseases and chronic infections.

Find detailed analytics on BRNS stock on TipRanks’ Stock Analysis page.